<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956459</url>
  </required_header>
  <id_info>
    <org_study_id>19 GENE 03</org_study_id>
    <nct_id>NCT03956459</nct_id>
  </id_info>
  <brief_title>Evaluation of PET-CT Scanner Performances to Detect Infra-centimetric Lesions in Patients With Cancer</brief_title>
  <acronym>IQversusMI</acronym>
  <official_title>Evaluation of PET-CT Scanner Performances to Detect Infra-centimetric Lesions in Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric study aiming to evaluate the PET-CT (Positron Emission Tomography -
      Computed Tomography) scanner performances to detect infra-centimetric lesions in two groups
      of patients with cancer and of different BMI (Body Mass Index) classes (BMI ≤ 25 and BMI &gt;
      25).

      For each patient, two consecutive PET-CT scanner will be performed using the &quot;Discovery MI&quot;
      and &quot;Discovery IQ&quot; PET-CT scanner systems.

      Virtual lesions will then be created on images obtained. Images will be interpreted by two
      independent observers.

      The study participation of each patient will be a maximum of 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative rate of virtual lesions detected by each system (&quot;Discovery MI&quot; and &quot;Discovery IQ&quot;)</measure>
    <time_frame>24 hours for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Inter-observer concordance in radiological images interpretation</measure>
    <time_frame>24 hours for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with a cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with a cancer for which a FDG-PET scanner must be performed</intervention_name>
    <description>For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:
&quot;Discovery MI&quot;
&quot;Discovery IQ&quot;
Only one contrast agent injection (FDG) will be given for both scanners.</description>
    <arm_group_label>Patients with a cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old.

          2. A patient with a cancer for which a FDG-PET (fluorodeoxyglucose-positron emission
             tomography) must be performed according to the standard practices

          3. OMS ≤ 1, Karnofsky Index &gt; 70.

          4. Negative pregnancy test at inclusion.

          5. Patient able to maintain a lying position in a strict supine position twice.

          6. Patient affiliated to a Social Health Insurance in France.

          7. Patient who has signed informed consent prior inclusion in the study and before any
             specific procedures for the study.

        Exclusion Criteria:

          1. Patient with unbalanced diabetic

          2. Patient with a formal contraindication usual for certain imaging procedures (severe
             claustrophobia, wearing a heart valve, pacemaker, etc.)

          3. Pregnant or breastfeeding woman

          4. Any psychological, family, geographical or sociological condition that does not allow
             medical follow-up and/or procedures provided for in the study protocol to be respected

          5. Patient protected by law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fréderic COURBON</last_name>
    <phone>05 31 15 56 18</phone>
    <email>courbon.frederic@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fréderic COURBON</last_name>
      <phone>05 31 15 56 18</phone>
      <email>courbon.frederic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FDG-PET</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

